# TxCell

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/txcell-s-a

- Industry: Biotechnology
- Headquarters: France
- Website: www.txcell.com
- Total disclosed funding: $25M
- Latest round: Series C (Oct 23, 2012)
- Investors on record: 7

## About

TxCell S.A. is a French biopharmaceutical company specializing in personalized immunotherapies, focused on developing advanced cell therapies to address chronic diseases, particularly cancer and autoimmune disorders.Founded in 2001 in France, TxCell S.A. develops innovative immunotherapies aimed at treating chronic diseases. The company has not undergone significant strategic pivots and does not have known subsidiaries. CEO Damian Marron leads the firm, which has completed 7 deals, with its most recent funding round being a Venture Debt of EUR 1.2 mn led by Bpifrance on April 14, 2014. TxCell has raised a total of EUR 16.2 mn to date through its funding rounds, including its IPO that raised EUR 16.2 mn by selling 2.9 million shares at EUR 5.58.TxCell specializes in advanced cell therapy solutions, primarily focusing on the development of personalized immunotherapies for patients with chronic diseases. Their core product offerings include T-cell immunotherapies designed to treat specific types of cancer and autoimmune diseases, leveraging the patient's immune system to target diseased cells. These therapies utilize proprietary technology to enhance T-cell specificity and efficacy, aiming to improve patient outcomes for conditions such as multiple sclerosis and various hematological malignancies. TxCell serves a diverse client base, including hospitals and biopharmaceutical companies in North America and Europe, where the demand for innovative therapeutic solutions is increasing.TxCell generates revenue through B2B partnerships with healthcare providers and pharmaceutical companies, primarily from licensing agreements for its proprietary technologies and therapeutic products. Revenue streams include milestone payments tied to clinical development phases and royalties on future product sales. TxCell's premium-priced flagship products reflect their innovative nature and the significant value they bring to chronic disease treatment protocols. Structured transactions involve upfront fees and recurring royalties, indicating a strategic focus on long-term collaboration in the healthcare sector.TxCell plans to leverage its recent funding to support the development of new immunotherapy products aimed at expanding its treatment portfolio. The company is targeting new markets, particularly in North America and Europe, by 2015 to capture growing demand for its advanced therapies. The recent Venture Debt funding will be utilized to enhance product development and market entry strategies following their IPO in April 2014, which raised EUR 16.2 mn.

## Funding rounds

- Series C, Oct 23, 2012, $12M — Auriga Partners, CDC Enterprises, Seventure Partners
- Series A, Oct 1, 2004, $13M — Auriga Partners, Ardian, Seventure Partners, Bioam Gestion, Innovation Capital, Inserm Transfert Initiative

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A, Series C
- Ardian (https://capitalatlas.ai/funds/ardian) — Series A
- Seventure Partners (https://capitalatlas.ai/funds/seventure-partners) — Series A, Series C
- Bioam Gestion (https://capitalatlas.ai/funds/bioam-gestion) — Series A
- Innovation Capital — Series A
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series A
- CDC Enterprises (https://capitalatlas.ai/funds/cdc-enterprises) — Series C